Showing results (141-150 of 209) with videos related to
Sort By:
Pageof 21
Cancer Immunology, Immunotherapy : CII|October 29, 2013
HER-2/neu vaccine-primed autologous T-cell infusions for the treatment of advanced stage HER-2/neu expressing cancersMary L Disis, Yushe Dang, Andrew L Coveler, et al.Oncotarget|December 16, 2016
Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigensLatha B Pathangey, Dustin B McCurry, Sandra J Gendler, et al.Molecular Cancer Therapeutics|March 6, 2008
Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunityVivian Goodell, James Waisman, Lupe G Salazar, et al.Clinical Pharmacology and Therapeutics|September 17, 2004
Diminishing the risk of nonrelapse mortality in hematopoietic stem cell transplantation: Prediction of exposure to the cyclophosphamide metabolite carboxyethylphosphoramide mustardRuolun Qiu, Amy Yao, Paolo Vicini, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 18, 2006
Real-time dose adjustment of cyclophosphamide in a preparative regimen for hematopoietic cell transplant: a Bayesian pharmacokinetic approachDavid H Salinger, Jeannine S McCune, Aaron G Ren, et al.Vaccines|February 26, 2025
A Phase II Study of Denileukin Diftitox in Patients with Advanced Treatment Refractory Breast CancerWilliam R Gwin, Lupe G Salazar, James Y Dai, et al.Journal of Translational Medicine|September 21, 2011
SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discoveryDavide Bedognetti, James M Balwit, Ena Wang, et al.Journal of Translational Medicine|June 3, 2014
Mining the pre-diagnostic antibody repertoire of TgMMTV-neu mice to identify autoantibodies useful for the early detection of human breast cancerJianning Mao, Jon Ladd, Ekram Gad, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2011
VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCCHailing Lu, Gregory N Dietsch, Maura-Ann H Matthews, et al.Cancer Research|June 20, 2015
An Autoimmune Response Signature Associated with the Development of Triple-Negative Breast Cancer Reflects Disease PathogenesisHiroyuki Katayama, Clayton Boldt, Jon J Ladd, et al.Pageof 21